2006
DOI: 10.1002/ajh.20790
|View full text |Cite
|
Sign up to set email alerts
|

Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study

Abstract: We designed a prospective study to evaluate the feasibility and efficacy of tandem highdose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL). Thirty-two patients were treated with salvage chemotherapy (IGEV, ifosfamide, gemcitabine, and vinorelbine) and chemo-sensitive patients received a first HDCT course with melphalan 200 mg/m 2 (MEL200) and a second BEAM course. The median time interval between the two HDCT courses was 66 days. The median number of reinfused CD34 + cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0

Year Published

2007
2007
2015
2015

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 25 publications
(19 citation statements)
references
References 34 publications
0
19
0
Order By: Relevance
“…The feasibility and the efficacy of tandem ASCT for patients with relapsed and/or refractory HL have been previously reported in several small sized studies, but to our knowledge, no study comparing single and tandem ASCT has been published. [10][11][12] The prospective H96 trial conducted by the GELA/SFGM group stratified patients at relapse according to the classical adverse prognostic factors and proposed either a single ASCT or a tandem ASCT with regard to the disease risk at relapse. The reported 5-year overall survival rates were 85% and 57% for the intermediate-risk and poor-risk groups, respectively, and the corresponding 5-year progression-free survival rates were 73% and 46%, respectively.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The feasibility and the efficacy of tandem ASCT for patients with relapsed and/or refractory HL have been previously reported in several small sized studies, but to our knowledge, no study comparing single and tandem ASCT has been published. [10][11][12] The prospective H96 trial conducted by the GELA/SFGM group stratified patients at relapse according to the classical adverse prognostic factors and proposed either a single ASCT or a tandem ASCT with regard to the disease risk at relapse. The reported 5-year overall survival rates were 85% and 57% for the intermediate-risk and poor-risk groups, respectively, and the corresponding 5-year progression-free survival rates were 73% and 46%, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…9 Several small retrospective studies showed that tandem ASCT is feasible and could also improve the outcome of patients with relapsed and/or refractory HL. [10][11][12] More recently, a risk-adapted treatment strategy based on adverse prognostic factors at relapse showed that tandem ASCT could improve survival in poorrisk patients. 13 The development of new methods, such as 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), are helpful for physicians, because they can provide a precise evaluation of disease response after treatment.…”
Section: Introductionmentioning
confidence: 99%
“…12,[24][25][26] In the setting of double HDC, a prospective study from the former GELA/SFGM group showed that, in the higher-risk group of patients (refractory and with more than two adverse prognostic factors), this approach of the 5-year freedom from second failure and OS was 41% and 52%, respectively, with the better results in those with chemosensitive disease to salvage therapy. 27 In a pilot study adopting the double HDC approach, Fung et al 28 reported that, in refractory or poor-prognosis patients, the 5-year OS, PFS and freedom from progression were 54%, 49% and 55%, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…The response rate increased with each step, from 47% after salvage chemotherapy, to 65% after first ASCT to 75% after second transplant. The 3-year FFP was 63% and the OS was 72% (Castagna, Magagnoli et al 2007). …”
Section: Tandem Autologous Transplantationmentioning
confidence: 96%